GlassScriptPhysician profile
Danny B Haddad
NPI 1235351297
$14,418.60
in general payments reported to CMS, 2019-2025
23 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $1,878 · 2021: $214 · 2022: $270 · 2023: $4,895 · 2024: $5,813 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,250 · Food and Beverage: $1,686 · Education: $45.00 · Travel and Lodging: $40.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,250.00 |
| Food and Beverage | $1,685.82 |
| Education | $45.00 |
| Travel and Lodging | $40.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,714.90 | 2019-2025 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $1,702.27 | 2019-2021 | |
| Amgen INC. | $605.11 | 2019-2025 | Krystexxa, Tavneos |
| Nxstage Medical, INC. | $204.89 | 2023-2025 | Liberty Select Cycler, Nxstage System One, Nxstage Cartridge Express |
| Otsuka America Pharmaceutical, INC. | $165.53 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Enterprises LLC | $156.78 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.89 | 2021-2024 | |
| Amarin Pharma, INC. | $117.07 | 2020 | |
| Opko Pharmaceuticals, LLC | $103.01 | 2019-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $90.21 | 2021-2024 | Benlysta, Jesduvroq, Nucala |
| Alexion Pharmaceuticals, INC. | $71.38 | 2019-2020 | |
| Travere Therapeutics, INC. | $63.53 | 2023-2025 | |
| Ardelyx, INC. | $47.90 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $41.33 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $37.97 | 2019-2025 | Velphoro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $35.93 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $34.48 | 2024 | |
| Akebia Therapeutics INC | $21.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.58 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.95 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $14.80 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.